Selected research
Industry Research
Human Factor VIII Concentrate Industry Research Report 2026
Market perspective
The global Human Factor VIII Concentrate market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Human Factor VIII Concentrate is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Human Factor VIII Concentrate is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Human Factor VIII Concentrate is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Human Factor VIII Concentrate include Shandong Taibang Biological Products, Shanghai Xinxing Medicine, Shanghai Raas Corp, Novo Nordisk A/S, Grifols, Pfizer, Hualan Biological, Bayer and SinoCell Tech, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Human Factor VIII Concentrate market in terms of revenue (US$ million) and, where applicable, sales volume (k units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Human Factor VIII Concentrate Market by Company
Shandong Taibang Biological Products
Shanghai Xinxing Medicine
Shanghai Raas Corp
Novo Nordisk A/S
Grifols
Pfizer
Hualan Biological
Bayer
SinoCell Tech
Shire (Baxter)
Octapharma
NovoNordisk
GC Pharma
CSL
Biogen
Human Factor VIII Concentrate Segment by Type
Blood Extraction
Recombine
Human Factor VIII Concentrate Segment by Application
Von Willebrand's Disease
Congenital Coagulation Factor VIII Deficiency
Acquired Factor VIII Deficiency
Human Factor VIII Concentrate Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Human Factor VIII Concentrate market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Human Factor VIII Concentrate and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Human Factor VIII Concentrate.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Human Factor VIII Concentrate manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Human Factor VIII Concentrate by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Human Factor VIII Concentrate in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Blood Extraction
- Recombine
Applications
- Von Willebrand's Disease
- Congenital Coagulation Factor VIII Deficiency
- Acquired Factor VIII Deficiency
Companies covered
- Shandong Taibang Biological Products
- Shanghai Xinxing Medicine
- Shanghai Raas Corp
- Novo Nordisk A/S
- Grifols
- Pfizer
- Hualan Biological
- Bayer
- SinoCell Tech
- Shire (Baxter)
- Octapharma
- NovoNordisk
- GC Pharma
- CSL
- Biogen
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Human Factor VIII Concentrate Market Size (2021-2032)
- 2.2.2 Global Human Factor VIII Concentrate Sales (2021-2032)
- 2.2.3 Global Human Factor VIII Concentrate Market Average Price (2021-2032)
- 2.3 Human Factor VIII Concentrate by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Blood Extraction
- 2.3.3 Recombine
- 2.4 Human Factor VIII Concentrate by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Von Willebrand's Disease
- 2.4.3 Congenital Coagulation Factor VIII Deficiency
- 2.4.4 Acquired Factor VIII Deficiency
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Human Factor VIII Concentrate Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Human Factor VIII Concentrate Sales (k units) of Manufacturers (2021-2026)
- 3.3 Global Human Factor VIII Concentrate Revenue of Manufacturers (2021-2026)
- 3.4 Global Human Factor VIII Concentrate Average Price by Manufacturers (2021-2026)
- 3.5 Global Human Factor VIII Concentrate Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Human Factor VIII Concentrate, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Human Factor VIII Concentrate, Product Type & Application
- 3.8 Global Manufacturers of Human Factor VIII Concentrate, Established Date
- 3.9 Global Human Factor VIII Concentrate Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Shandong Taibang Biological Products
- 4.1.1 Shandong Taibang Biological Products Company Information
- 4.1.2 Shandong Taibang Biological Products Business Overview
- 4.1.3 Shandong Taibang Biological Products Human Factor VIII Concentrate Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Shandong Taibang Biological Products Human Factor VIII Concentrate Product Portfolio
- 4.1.5 Shandong Taibang Biological Products Recent Developments
- 4.2 Shanghai Xinxing Medicine
- 4.2.1 Shanghai Xinxing Medicine Company Information
- 4.2.2 Shanghai Xinxing Medicine Business Overview
- 4.2.3 Shanghai Xinxing Medicine Human Factor VIII Concentrate Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Shanghai Xinxing Medicine Human Factor VIII Concentrate Product Portfolio
- 4.2.5 Shanghai Xinxing Medicine Recent Developments
- 4.3 Shanghai Raas Corp
- 4.3.1 Shanghai Raas Corp Company Information
- 4.3.2 Shanghai Raas Corp Business Overview
- 4.3.3 Shanghai Raas Corp Human Factor VIII Concentrate Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Shanghai Raas Corp Human Factor VIII Concentrate Product Portfolio
- 4.3.5 Shanghai Raas Corp Recent Developments
- 4.4 Novo Nordisk A/S
- 4.4.1 Novo Nordisk A/S Company Information
- 4.4.2 Novo Nordisk A/S Business Overview
- 4.4.3 Novo Nordisk A/S Human Factor VIII Concentrate Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Novo Nordisk A/S Human Factor VIII Concentrate Product Portfolio
- 4.4.5 Novo Nordisk A/S Recent Developments
- 4.5 Grifols
- 4.5.1 Grifols Company Information
- 4.5.2 Grifols Business Overview
- 4.5.3 Grifols Human Factor VIII Concentrate Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Grifols Human Factor VIII Concentrate Product Portfolio
- 4.5.5 Grifols Recent Developments
- 4.6 Pfizer
- 4.6.1 Pfizer Company Information
- 4.6.2 Pfizer Business Overview
- 4.6.3 Pfizer Human Factor VIII Concentrate Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Pfizer Human Factor VIII Concentrate Product Portfolio
- 4.6.5 Pfizer Recent Developments
- 4.7 Hualan Biological
- 4.7.1 Hualan Biological Company Information
- 4.7.2 Hualan Biological Business Overview
- 4.7.3 Hualan Biological Human Factor VIII Concentrate Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Hualan Biological Human Factor VIII Concentrate Product Portfolio
- 4.7.5 Hualan Biological Recent Developments
- 4.8 Bayer
- 4.8.1 Bayer Company Information
- 4.8.2 Bayer Business Overview
- 4.8.3 Bayer Human Factor VIII Concentrate Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Bayer Human Factor VIII Concentrate Product Portfolio
- 4.8.5 Bayer Recent Developments
- 4.9 SinoCell Tech
- 4.9.1 SinoCell Tech Company Information
- 4.9.2 SinoCell Tech Business Overview
- 4.9.3 SinoCell Tech Human Factor VIII Concentrate Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 SinoCell Tech Human Factor VIII Concentrate Product Portfolio
- 4.9.5 SinoCell Tech Recent Developments
- 4.10 Shire (Baxter)
- 4.10.1 Shire (Baxter) Company Information
- 4.10.2 Shire (Baxter) Business Overview
- 4.10.3 Shire (Baxter) Human Factor VIII Concentrate Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Shire (Baxter) Human Factor VIII Concentrate Product Portfolio
- 4.10.5 Shire (Baxter) Recent Developments
- 4.11 Octapharma
- 4.11.1 Octapharma Company Information
- 4.11.2 Octapharma Business Overview
- 4.11.3 Octapharma Human Factor VIII Concentrate Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 Octapharma Human Factor VIII Concentrate Product Portfolio
- 4.11.5 Octapharma Recent Developments
- 4.12 NovoNordisk
- 4.12.1 NovoNordisk Company Information
- 4.12.2 NovoNordisk Business Overview
- 4.12.3 NovoNordisk Human Factor VIII Concentrate Sales, Revenue and Gross Margin (2021-2026)
- 4.12.4 NovoNordisk Human Factor VIII Concentrate Product Portfolio
- 4.12.5 NovoNordisk Recent Developments
- 4.13 GC Pharma
- 4.13.1 GC Pharma Company Information
- 4.13.2 GC Pharma Business Overview
- 4.13.3 GC Pharma Human Factor VIII Concentrate Sales, Revenue and Gross Margin (2021-2026)
- 4.13.4 GC Pharma Human Factor VIII Concentrate Product Portfolio
- 4.13.5 GC Pharma Recent Developments
- 4.14 CSL
- 4.14.1 CSL Company Information
- 4.14.2 CSL Business Overview
- 4.14.3 CSL Human Factor VIII Concentrate Sales, Revenue and Gross Margin (2021-2026)
- 4.14.4 CSL Human Factor VIII Concentrate Product Portfolio
- 4.14.5 CSL Recent Developments
- 4.15 Biogen
- 4.15.1 Biogen Company Information
- 4.15.2 Biogen Business Overview
- 4.15.3 Biogen Human Factor VIII Concentrate Sales, Revenue and Gross Margin (2021-2026)
- 4.15.4 Biogen Human Factor VIII Concentrate Product Portfolio
- 4.15.5 Biogen Recent Developments
5 Global Human Factor VIII Concentrate Market Scenario by Region
- 5.1 Global Human Factor VIII Concentrate Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Human Factor VIII Concentrate Sales by Region: 2021-2032
- 5.2.1 Global Human Factor VIII Concentrate Sales by Region: 2021-2026
- 5.2.2 Global Human Factor VIII Concentrate Sales by Region: 2027-2032
- 5.3 Global Human Factor VIII Concentrate Revenue by Region: 2021-2032
- 5.3.1 Global Human Factor VIII Concentrate Revenue by Region: 2021-2026
- 5.3.2 Global Human Factor VIII Concentrate Revenue by Region: 2027-2032
- 5.4 North America Human Factor VIII Concentrate Market Facts & Figures by Country
- 5.4.1 North America Human Factor VIII Concentrate Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Human Factor VIII Concentrate Sales by Country (2021-2032)
- 5.4.3 North America Human Factor VIII Concentrate Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Human Factor VIII Concentrate Market Facts & Figures by Country
- 5.5.1 Europe Human Factor VIII Concentrate Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Human Factor VIII Concentrate Sales by Country (2021-2032)
- 5.5.3 Europe Human Factor VIII Concentrate Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Human Factor VIII Concentrate Market Facts & Figures by Country
- 5.6.1 Asia Pacific Human Factor VIII Concentrate Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Human Factor VIII Concentrate Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Human Factor VIII Concentrate Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Human Factor VIII Concentrate Market Facts & Figures by Country
- 5.7.1 South America Human Factor VIII Concentrate Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Human Factor VIII Concentrate Sales by Country (2021-2032)
- 5.7.3 South America Human Factor VIII Concentrate Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.8 Middle East and Africa Human Factor VIII Concentrate Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Human Factor VIII Concentrate Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Human Factor VIII Concentrate Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Human Factor VIII Concentrate Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Human Factor VIII Concentrate Sales by Type (2021-2032)
- 6.1.1 Global Human Factor VIII Concentrate Sales by Type (2021-2032) & (k units)
- 6.1.2 Global Human Factor VIII Concentrate Sales Market Share by Type (2021-2032)
- 6.2 Global Human Factor VIII Concentrate Revenue by Type (2021-2032)
- 6.2.1 Global Human Factor VIII Concentrate Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Human Factor VIII Concentrate Revenue Market Share by Type (2021-2032)
- 6.3 Global Human Factor VIII Concentrate Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Human Factor VIII Concentrate Sales by Application (2021-2032)
- 7.1.1 Global Human Factor VIII Concentrate Sales by Application (2021-2032) & (k units)
- 7.1.2 Global Human Factor VIII Concentrate Sales Market Share by Application (2021-2032)
- 7.2 Global Human Factor VIII Concentrate Revenue by Application (2021-2032)
- 7.2.1 Global Human Factor VIII Concentrate Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Human Factor VIII Concentrate Revenue Market Share by Application (2021-2032)
- 7.3 Global Human Factor VIII Concentrate Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Human Factor VIII Concentrate Value Chain Analysis
- 8.1.1 Human Factor VIII Concentrate Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Human Factor VIII Concentrate Production Mode & Process
- 8.2 Human Factor VIII Concentrate Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Human Factor VIII Concentrate Distributors
- 8.2.3 Human Factor VIII Concentrate Customers
9 Global Human Factor VIII Concentrate Analyzing Market Dynamics
- 9.1 Human Factor VIII Concentrate Industry Trends
- 9.2 Human Factor VIII Concentrate Industry Drivers
- 9.3 Human Factor VIII Concentrate Industry Opportunities and Challenges
- 9.4 Human Factor VIII Concentrate Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst